Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
Neurology(R) Neuroimmunology & Neuroinflammation|September 4, 2024
Impact of the Multiple Sclerosis-Associated Genetic Variant CD226 Gly307Ser on Human CD8 T-Cell FunctionsElena Morandi, Véronique Adoue, Isabelle Bernard, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 23, 2015
NK cells require IL-28R for optimal in vivo activityFernando Souza-Fonseca-Guimaraes, Arabella Young, Deepak Mittal, et al.
Nature Immunology|March 25, 2014
The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functionsChristopher J Chan, Ludovic Martinet, Susan Gilfillan, et al.
Cancer Research|October 30, 2014
Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanomaLucas Ferrari de Andrade, Shin F Ngiow, Kimberley Stannard, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|November 2, 2006
Design of phosphorylated dendritic architectures to promote human monocyte activationMary Poupot, Laurent Griffe, Patrice Marchand, et al.
Cell Reports|March 31, 2015
DNAM-1 expression marks an alternative program of NK cell maturationLudovic Martinet, Lucas Ferrari De Andrade, Camille Guillerey, et al.
Blood Advances|October 29, 2021
Toll-like receptor 4 selective inhibition in medullar microenvironment alters multiple myeloma cell growthLéa Lemaitre, Malik Hamaidia, Jean-Gérard Descamps, et al.
Clinical Pharmacology and Therapeutics|June 17, 2026
Patient-Centric First-in-Human Dose Selection: An Ex Vivo Minimal Anticipated Biological Effect Level Approach for T-Cell Engagers in Multiple MyelomaThomas E Kraft, Estelle Marrer-Berger, Sara Belli, et al.
Blood|June 14, 2024
NK cells with adhesion defects and reduced cytotoxic functions are associated with a poor prognosis in multiple myelomaEve Blanquart, Rüçhan Ekren, Bineta Rigaud, et al.
Cancer Cell|March 20, 2018
Dysregulated IL-18 Is a Key Driver of Immunosuppression and a Possible Therapeutic Target in the Multiple Myeloma MicroenvironmentKyohei Nakamura, Sahar Kassem, Alice Cleynen, et al.
Pageof 5